Strofantin-G (g-strophanthin) 0.025% 1ml. ampoules №10


Acute heart failure, chronic heart failure IIb-i stage (i-IV stage according to NYHA classification), supraventricular tachycardia, atrial fibrillation.



Release form, composition
The drug Strofantin G is an injection solution that is produced in the form of a clear, colorless liquid.
The drug contains the active ingredient: strophanthin G 0.25 mg.
Additional components: sodium hydroxide, citric acid monohydrate, water for injection.
Pharmacological properties
The drug Strofantin G belongs to the group of cardiotonic drugs.
The action of the drug promotes an increase in the speed and strength of myocardial contractility, a decrease in AV conduction, an increase in stroke and cardiac output, a decrease in heart rate, an improvement in ventricular release, which ultimately leads to an improvement in blood circulation.
Indications for use
The drug Strofantin G is used and prescribed as part of complex treatment for chronic heart failure stage II (with classical manifestations) and stage III-IV according to the NYHA classification, acute heart failure, atrial fibrillation, supraventricular tachycardia.
It is contraindicated to inject a solution of Strofantin G in the presence of such diseases:

  • glycosidic intoxication;
  • hypersensitivity to components;
  • constrictive pericarditis;
  • ventricular tachycardia;
  • acute myocardial infarction;
  • severe bradycardia;
  • sick sinus syndrome;
  • AV block II and III degrees;
  • hypercalcemia and hypokalemia;
  • hypertrophic obstructive cardiomyopathy;
  • isolated mitral stenosis;
  • pericarditis;
  • endocarditis;
  • acute myocarditis;
  • carotid sinus syndrome;
  • severe cardiosclerosis;
  • Wolff-Parkinson-White syndrome;
  • aneurysm of the thoracic aorta;
  • children under 18 years of age.

Pregnancy and breastfeeding period
The introduction of the drug Strofantin G during pregnancy and lactation is contraindicated.
Mode of application
The drug Strofantin G is intended for intravenous use.
The recommended dose for adult patients is 1-2 ml of the drug, which is previously diluted in 10-20 ml of 0.9% sodium chloride solution.
If possible, it is advisable to inject the drug intravenously at a dosage of 1 ml diluted in 100 ml of 0.9% sodium chloride solution or 5% glucose solution.
If there is a need, a single dose can be increased, but not more than 2 ml (0.5 mg), the maximum daily dose should not exceed 4 ml (1 mg).
In case of an overdose of the drug Strofantin G, the following are possible: cardiac arrhythmias and blockade, including bradycardia, ventricular extrasystole, ventricular paroxysmal tachycardia, polytopic gastric tachycardia, in especially severe cases, cardiac arrest and the development of ventricular fibrillation are possible;
Also, drug poisoning can cause: anorexia, vomiting, nausea, diarrhea, headache, intestinal wall necrosis, dizziness, neuritis, paresthesia, sciatica, decreased visual acuity, yellow and green color of the surrounding objects, scotomas, micro- and macropsia.
Very rarely, the administration of the solution leads to confusion, syncope and manic-depressive syndrome.
Adverse reactions
The use of the drug Strofantin G can lead to the occurrence of such side effects: headache, confusion, dizziness, increased fatigue, sleep disturbances, drowsiness, mental disorders, visual impairment, nausea, loss of appetite, vomiting and diarrhea.
Also possible manifestations: thrombocytopenic purpura, petechiae, nosebleeds, conduction and heart rhythm disturbances, anaphylactic reactions, allergic reactions, urticaria, changes at the injection site.
In rare cases, a brigian heart attack and gynecomastia in men may occur.
Storage conditions
Storage of the drug Strofantin G does not require any special conditions: temperature not higher than +25 ° C, original packaging, dry and dark place, inaccessible to children.
The shelf life of the tablets is 5 years.